NICE, In Final Decision, Rejects Roche's Tarceva For Lung Cancer Maintenance
This article was originally published in The Pink Sheet Daily
Executive Summary
The benefits of Roche's Tarceva as maintenance therapy for lung cancer are uncertain and the drug is not cost-effective, the U.K.'s cost regulator concludes in final guidance.
You may also be interested in...
NICE Doubtful On Cost-Effectiveness Of Tarceva
The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.
Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.